A detailed clinical timeline is displayed (A, top panel). A PET/CT on June 8, 2012 demonstrated disease progression prompting a change in the patient's chemotherapy regimen. On June 15, 2012, the patient was started on a chemotherapy regimen containing gemcitabine and vinorelbine. The green marker demarcates the treatment timeline for gemcitabine and vinorelbine (A, top panel). A repeat PET/CT on August 6, 2012, demonstrated continued disease progression. From August 22, 2012 to August 31, 2012 the patient was treated with concurrent RT and ipilimumab. Afterward, he received 3 additional cycles of ipilimumab alone. The blue marker demarcates the treatment timeline for RT and ipilimumab (A [top panel] and B) and data plotted to the right of the vertical dashed line in each graph represents post initiation of RT and ipilimumab treatment (A [bottom 3 panels] and B). The final dose of ipilimumab was given on October 26, 2012. Imaging on November 8, 2012 (CT of the chest abdomen and pelvis) and January 17, 2013 (PET/CT) demonstrated significant treatment responses. During the course of treatment, the patient had serial blood draws. The results of the peripheral absolute blood cell counts (white blood cells [WBCs], ALCs, and AECs) are displayed as number of cells [×103] per μL of whole blood (A, bottom 3 panels), in accordance with the aforementioned treatment timeline (A, top panel). A dramatic drop in CEA levels (a non-specific tumor marker) was observed after treatment with RT and ipilimumab (B). The marker peaked at 119.6 ng/ml (normal levels 0-5 ng/ml) on September 7, 2012, demonstrated a dramatic drop to 5.8 ng/ml on October 26, 2012, and thereafter was maintained at normal levels.